



CytoTools AG is planning a capital increase to finance the European phase III study of the wound healing agent DermaPro®

- Capital increase from authorized capital totalling 25% of share capital
- 373,087 new shares issued at € 13.30 with subscription rights for existing shareholders
- Gross proceeds of approx. € 4.96 million intended to secure the financing of the planned European phase III study of the wound healing agent DermaPro®
- Anchor investors agree to subscribe around one quarter of the capital increase

Darmstadt, November 10, 2011 – CytoTools AG, a technology holding company with investments in the fields of pharmaceuticals and medical products, is planning a capital increase totalling 25% of existing share capital. The Managing Directors and Supervisory Board have decided to use part of the authorized capital from the resolution at the Annual General Meeting on August 9, 2011 and issue a total of 373,087 new no-par bearer shares in exchange for cash. The price of the new shares has been fixed at € 13.30 per share, thus the company receives gross proceeds of around € 4.96 million if all new shares are placed. The new shares with a notional par value of € 1.00 have full dividend rights for the current financial year 2011. As part of the non-public offering, the existing shareholders will receive indirect subscription rights of 4:1, i.e. for four existing shares, they are permitted to acquire one new share. The subscription offer will be published in the electronic German Federal Gazette (Bundesanzeiger) today. There is no provision for trading these subscription rights.

The two-week subscription period for new shares is planned to start on November 14, 2011 and will run up to and including November 25, 2011. The existing shareholders will – subject to allocation – have the option of oversubscribing, i.e. subscribe more shares than allowed by their subscription rights. Institutional investors have already expressed their interest in purchasing a stake in CytoTools AG and have agreed to subscribe around one quarter of the capital increase. In addition, unsubscribed shares will be offered to institutional investors as part of a private placement. By successfully completing the capital increase, the share capital of CytoTools AG will rise by a total of 25% from € 1,492,350 to € 1,865,437. The transaction is being supported by lead manager Donner & Reuschel AG.

The additional equity is to be exclusively used as financing for the subsidiary DermaTools Biotech GmbH to realise the planned European phase III study of the DermaPro® agent. The study, which was extended into centres in Latvia and Lithuania in the summer, is quickly progressing through phase IIb, with completion of this phase expected in the first quarter of 2012. After successful evaluation and positive study results, the agent could receive approval to begin the decisive phase III of the study. The desired proceeds from the capital increase would secure the financing for this European study, allowing the company to drive towards a market launch of DermaPro® after successfully completing phase III.

Dr. Mark-Andre Freyberg, Managing Director of CytoTools AG, explains the motives behind the capital increase: "This measure is intended to help sustain the rapid development of our wound

PRESS INFORMATION



CytoTools

healing agent DermaPro® towards market launch. After the agent already demonstrated high tolerance levels and major healing potential in parallel Indian studies, the ongoing preparations for the European phase III study should also form the basis for approval in other large pharmaceuticals markets."

Company information:

CytoTools AG, previously CytoTools GmbH, is a technology and holding company which holds the following shares in its subsidiaries which carry out product development in the pharmaceutical and medical products field: 51,5% in DermaTools Biotech GmbH (therapy field dermatology, urology) and 46% in CytoPharma GmbH (therapy field cardiovascular disease, cancer). The complete know-how is protected by corresponding basic patents which are maintained worldwide by CytoTools AG and transferred to the subsidiary companies in the form of exclusive licenses.

Disclaimer:

This information is neither an offer for sale nor an instruction to buy securities of CytoTools AG. The information included in this press release is exclusively for persons who are residents of and are domiciled in Germany. Securities of CytoTools AG have not been and are not registered under the U.S. Securities Act of 1933 in the current applicable version, and may neither be offered nor sold in the United States of America. The information included in this press release may not be disseminated in the United States of America, and may not be passed on to U.S. persons – as defined in Regulation S of the U.S. Securities Act of 1933 in the current applicable version.

Contact:

CytoTools AG
Dr. Mark-Andre Freyberg
Klappacher Str. 126
64285 Darmstadt
Tel.: +49-6151-95158-12
Fax: +49-6151-95158-13
E-Mail: freyberg@cytotools.de

Press contact:

cometis AG
Ulrich Wiehle
Unter den Eichen 7
65195 Wiesbaden
Tel.: +49-611-205855-11
Fax: +49-611-205855-66
E-Mail: wiehle@cometis.de